1. Home
  2. Studies
  3. CDT : Clinical Studies (index)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...

 		Oncology Phase II Completed 03 June 2005 09 December 2010

Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma

 		Oncology Phase II Completed 11 July 2005 03 February 2009

The effect of Minalcipran 100mg BID on sensitivity to stimulus-evoked pain in patients with Fibromyalgia : a FMRI neuroimaging study

 		Central Nervous System Phase II Completed 21 October 2005 26 April 2007

Efficacy and safety assessment of 6 months (24 weeks) treatment with Structum® 500 mg capsule bid in hip osteoarthritis: multicenter randomised double blind parallel group and placebo controlled study

 		Rhumatology Phase IV Completed 17 November 2005 07 November 2006

Randomised, placebo-controlled, double-blind efficacy study of the emollient V0034CR in addition to a moderately potent corticosteroid in the acute phase of treatment of atopic dermatitis in infants

 		Dermatology Phase III Completed 19 November 2005 22 June 2006
11 - 15 over 126

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA

 

 

 

 

Studies status

Lorem ipsum dolor

Sed hendrerit lorem augue, at molestie ligula dapibus id. Phasellus eu ullamcorper diam.

Lorem ipsum dolor

Sed at augue ut ex tempor congue convallis sed orci. Suspendisse congue pellentesque velit non convallis. Integer nec risus eu urna finibus ornare nec nec eros.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Integer vel tortor sapien. Nulla elit tellus, interdum vitae lobortis id, scelerisque nec elit. Donec ut maximus nibh. Nunc sit amet nibh nec leo scelerisque tempus id sed nisi. Duis vehicula sem sit amet elit cursus, nec ultrices turpis cursus.

Lorem ipsum dolor

Donec eget ultrices justo. Donec posuere, nibh quis dignissim feugiat, ante turpis pharetra sapien, vel faucibus magna leo eu quam. Fusce sed massa sapien.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Nunc congue diam metus, id hendrerit nulla fringilla non. Nullam non interdum dui. Phasellus quis dapibus erat. Aliquam metus ipsum, luctus nec mollis vitae, varius ut massa.